{"transactions":[{"id":986630,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":72510,"kind":"person","name":"Yu John S","position":1,"cik":"0001550545","reported_name":"Yu John S","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and Chairman"}}],"security":"COMMON STOCK","published_at":"2025-11-26T17:24:11.000Z","date":"2025-10-08","kind":"grant","planned":false,"acquired":true,"shares":190840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 190,840 restricted stock units (\"RSUs\") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 190,840 RSUs are scheduled to vest in full on the first anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of (1) 34,599 shares of common stock (2) 195,506 RSUs which remain subject to vesting."}],"balance_after":230105,"source":{"system":"sec-edgar","filing":"0001493152-25-025197","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1550545/000149315225025197/ownership.xml","form_type":"4"}},{"id":1249022,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":72510,"kind":"person","name":"Yu John S","position":1,"cik":"0001550545","reported_name":"Yu John S","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and Chairman"}}],"security":"COMMON STOCK","published_at":"2025-02-24T18:51:39.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 14,000 restricted stock units (\"RSUs\") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 14,000 RSUs are scheduled to vest in one third increments on each of 01/01/2025, 09/16/2025, and 09/16/2026. Accordingly, 4,667 RSUs have vested as of the date hereof."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of (1) 5,346,504 shares of common stock and (2) 9,334 RSUs which remain subject to vesting."}],"balance_after":5355838,"source":{"system":"sec-edgar","filing":"0001493152-25-008105","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1550545/000149315225008105/ownership.xml","form_type":"4"}},{"id":1355562,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":72510,"kind":"person","name":"Yu John S","position":1,"cik":"0001550545","reported_name":"Yu John S","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and Chairman"}}],"security":"COMMON STOCK","published_at":"2024-11-21T21:53:44.000Z","date":"2024-11-20","kind":"purchase","planned":false,"acquired":true,"shares":4000,"price":1.44,"value":5760.0,"ownership":{"direct":true},"balance_after":5341837,"source":{"system":"sec-edgar","filing":"0001493152-24-047261","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1550545/000149315224047261/ownership.xml","form_type":"4"}},{"id":3900903,"issuer":{"id":165907,"kind":"organization","name":"ImmunoCellular Therapeutics, Ltd.","symbol":"IMUC"},"owners":[{"id":72510,"kind":"person","name":"Yu John S","position":1,"cik":"0001550545","reported_name":"Yu John S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-08T16:07:20.000Z","date":"2018-06-06","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of ImmunoCellular Therapeutics Ltd. common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"The restricted stock unit shall be fully vested and immediately exercisable on the grant date."}],"balance_after":120250,"source":{"system":"sec-edgar","filing":"0001209191-18-036656","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/822411/000120919118036656/doc4.xml","form_type":"4"}}]}